Castellano | Euskara | Français | English
DAR No 1: Nicotinic acid / Laropiprant
Share it
A new look at old junk
- Nicotinic acid/laropiprant is indicated in the treatment of dyslipidaemia.
- No comparative data on efficacy is available between nicotinic acid/laropiprant and the different statins. The administration of this drug in combination with statin therapy at low to medium doses produces a greater reduction in LDL-c levels than in monotherapy.
- There is no data available on the combination with high dose statins. There is no evidence available on the efficacy of nicotinic acid/laropiprant with regard to the reduction in morbimortality.
- Flushing still remains the most frequent undesirable effect related to nicotinic acid, despite its association with laropiprant.
